Evaluation of long-term adverse cardiovascular events risk after elective percutaneous coronary intervention

Objective. The aim of our study was to analyze long-term outcomes, to identify their predictors and to develop a model for determining the risk of long-term adverse сardiovascular events after elective percutaneous coronary interventions (PCI). Materials and Methods. A retrospective study included 151 patients 6 years after the elective PCI. Outcomes were assessed by analyzing medical records and telephone interviews. The primary composite end point of the study was a major adverse cardiovascular event (MACCE), including death from cardiovascular causes, acute coronary syndrome, acute cerebrovascular accident. Results. Death from cardiovascular events was reported in 10.6% of patients, acute coronary syndrome occurred in 34.4%, stroke - in 6.6%. Thus MAСCE occurred in 40.4% of patients. MACCE predictors in the long-term period were chronic kidney disease, contrast-induced acute kidney injury, baseline C-reactive protein more than 5.5 mg/l. Restenosis of previously installed stents increases the risk of MACCE at 8.09 times, chronic obstructive pulmonary disease - 3.4 times PT - 2.84 times, family history for cardiovascular disease (CVD) - in 2.94 times, a very high risk of contrast-induced nephropathy (CIN) (≥11 points on the R. Mehran scale) - 2.15 times. The most significant MACCE’s predictors identified using stepwise logistic regression and included in the developed model are: family history for CVD, statins reception during the procedure of PCI, the initial level of postprandial blood glucose, high risk of CIN (11-15 points on a scale of R. Mehran). AUC values for the found model was 0.852 [95% CI 0.749-0.956]. Conclusion. The use of our model of risk stratification in patients after elective PCI allows, on the basis of simple clinical characteristics, to distinguish groups of patients with a high residual risk of adverse cardiovascular events that require the timely application of more active follow-up strategies.

ишемическая болезнь сердца, плановые чрескожные коронарные вмешательства, оценка риска отдаленных исходов, coronary heart disease, elective percutaneous coronary intervention, evaluation of long-term adverse events

1. Roffi M, Patrono C, Collet J-P, Mueller C, Valgimigli M, Andreotti F et al. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Seg ment Elevation of the European Society of Cardiology (ESC). Eur Heart J. 2016,37 (3):267-315. DOI:10.1093 /eurheartj/ehv320

2. Bonaca MP, Bhatt DL, Cohen M, Steg PG, Storey RF, Jensen EC et al. Long-Term Use of Ticagrelor in Patients with Prior Myocardial Infarction. New England Journal of Medicine. 2015,372 (19):1791-800. DOI:10.1056/NEJMoa1500857

3. Cannon CP, Blazing MA, Giugliano RP, McCagg A., White JA, Theroux P. et al. Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. New England Journal of Medicine. 2015,372 (25):2387-97. DOI: 10.1056/NEJMoa1410489

4. Sabatine MS, Giugliano RP, Keech AC, Honarpour N., Wiviott SD, Murphy SA et al. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. New England Journal of Medicine. 2017,376 (18): 1713-22. DOI:10.1056/NEJMoa1615664

5. Stone GW, Ellis SG, Colombo A., Grube E., PopmaJJ, Uchida T. et al. Long-Term Safety and Efficacy of Paclitaxel-Eluting Stents. JACC: Cardiovascular Interventions. 2011,4 (5):530-42. DOI:10.1016/j. jcin. 2011.03.005

6. Grayson A.D. Multivariate prediction of major adverse cardiac events after 9914 percutaneous coronary interventions in the north west of England. Heart. 2006,92 (5):658-63. DOI:10.1136/hrt. 2005.066415

7. Vershinina EO, Repin AN, Salnikova E.S. Loading doses of statins in elective endovascular interventions on coronary arteries. Russian Heart Journal. 2016,15 (3):181-91. DOI:10.18087/rhj. 2016.3.2181

8. Rapsomaniki E., Shah A., Perel P., Denaxas S., George J., Nicholas O. et al. Prognostic models for stable coronary artery disease based on electronic health record cohort of 102023 patients. European Heart Journal. 2014,35 (13):844-52. DOI:10.1093/eurheartj/eht533

9. Roe MT, Goodman SG, Ohman EM, Stevens SR, Hochman JS, Gottlieb S. et al. Elderly Patients With Acute Coronary Syndromes Managed Without Revascularization: Insights Into the Safety of Long-Term Dual Antiplatelet Therapy With Reduced-Dose Prasugrel Versus Standard-Dose Clopidogrel. Circulation. 2013,128 (8):823-33. DOI:10.1161/CIRCULA-TIONAHA. 113.002303

10. Mueller C., Neumann F-J, Roskamm H., Buser P., Hodgson JM, Perruchoud AP et al. Women do have an improved long-term outcome after non-ST-elevation acute coronary syndromes treated very early and predominantly with percutaneous coronary intervention: a prospective study in 1,450 consecutive patients. J. Am Coll Cardiol. 2002,40 (2):245-50. PMID:12106927

11. Вершинина Е. О., Репин А. Н., Рябова Т. Р., Гольцов С. Г. Ближайшие и отдаленные результаты плановых эндоваскулярных вмешательств на коронарных артериях и влияние на них нарушений углеводного обмена. Сибирский медицинский журнал (Томск). 2013,28 (4):28-35.

12. Bhatt DL, Flather MD, Hacke W., Berger PB, Black HR, Boden WE et al. Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial. J. Am Coll Cardiol. 2007,49 (19):1982-8. DOI:10.1016/j. jacc. 2007.03.025

13. Вершинина Е. О., Репин А. Н., Рябова Т. Р. Влияние мультифокального атеросклероза на ближайшие и отдаленные результаты планового эндоваскулярного лечения ИБС. Сибирский Медицинский Журнал (г Томск). 2014,29 (3):87-93.

14. Amarenco P., Lavallee PC, Labreuche J., Ducrocq G., Juliard J-M, Feldman L. et al. Coronary Artery Disease and Risk of Major Vascular Events After Cerebral Infarction. Stroke. 2013,44 (6) : 1505-11. DOI: 10.1161/STROKEAHA. 111.000142

15. James S., Budaj A., Aylward P., Buck KK, Cannon CP, Cornel JH et al. Ticagrelor Versus Clopidogrel in Acute Coronary Syndromes in Relation to Renal Function: Results From the Platelet Inhibition and Patient Outcomes (PLATO) Trial. Circulation. 2010,122 (11):1056-67. DOI: 10.1161/CIRCULATIONAHA. 109.933796

16. Beygui F., Silvain J., Pena A., Bellemain-Appaix A., Collet J-P, Drexler H., et al. Usefulness of Biomarker Strategy to Improve GRACE Score’s Prediction Performance in Patients With Non - ST-Segment Elevation Acute Coronary Syndrome and Low Event Rates. The American Journal of Cardiology. 2010,106 (5):650-8. DOI:10.1016/j. amjcard. 2010.04.019

17. Wauters E., Carruthers KF, Buysschaert I., Dunbar DR, Peuteman G., Belmans A. et al. Influence of 23 coronary artery disease variants on recurrent myocardial infarction or cardiac death: the GRACE Genetics Study. European Heart Journal. 2013,34 (13):993-1001. DOI:10.1093/eurheartj/ehs389

18. Palmerini T., Caixeta A., Genereux P., Cristea E., Lansky A., Mehran R. et al. Comparison of clinical and angiographic prognostic risk scores in patients with acute coronary syndromes: Analysis from the Acute Catheterization and Urgent Intervention Triage StrategY (ACUITY) trial. American Heart Journal. 2012,-163 (3):383-391. e5. DOI:10.1016 /j. ahj. 2011.11.010

19. Nakatani D., Sakata Y., Suna S., Usami M., Matsumoto S., Shimizu M. et al. Incidence, Predictors, and Subsequent Mortality Risk of Recurrent Myocardial Infarction in Patients Following Discharge for Acute Myocardial Infarction. Circulation Journal. 2013,77 (2):439-46. DOI:10.1253/circj. CJ-11-1059

20. Riegger J., Byrne R.A., Joner M., Chandraratne S., Gershlick AH, Ten Berg JM et al. Histopathological evaluation of thrombus in patients presenting with stent thrombosis. A multicenter European study: a report of the prevention oflate stent thrombosis by an interdisciplinary global European effort consortium. Eur Heart J. 2016,37 (19):1538-49. DOI:10.1093/eur-heartj/ehv419

21. Otsuka F., Byrne R.A., Yahagi K., Mori H., Ladich E., Fowler DR et al. Neoatherosclerosis: overview ofhistopathologic findings and implications for intravascular imaging assessment. European Heart Journal. 2015,36 (32):2147-59.DOI:10.1093/eurheartj/ehv205

22. Palhais N., Arroyo D., Lehmann S., Togni M., Kaufmann U., Puricel S-G et al. Ten-year clinical follow-up after sirolimus-eluting stent implantation. American Heart Journal. 2014,167 (6):893-9. DOI:10.1016/j. ahj. 2013.12.013

23. Yamaji K., Räber L., Zanchin T., Spitzer E., Zanchin C., Pilgrim T. et al. Ten-year clinical outcomes of first-generation drug-eluting stents: the Sirolimus-Eluting vs. Paclitaxel-Eluting Stents for Coronary Revascularization (SIRTAX) VERY LATE trial. European HeartJournal. 2016-37 (45):3386-95. DOI:10.1093/eurheartj/ehw343

24. Hu W-S, Lee J-H, Tsai M-K, Wen C-P. A novel cardiovascular death prediction model for Chinese individuals: A prospective cohort study of 381,963 study participants. Atherosclerosis. 2017,264:19-28. DOI:10.1016/j. atherosclerosis. 2017.07.016

25. Eagle R.A., Lim MJ, Dabbous OH, Pieper KS, Goldberg RJ, Van de Werf F. et al. A Validated Prediction Model for All Forms of Acute Coronary Syndrome: Estimating the Risk of 6-Month Postdischarge Death in an International Registry. JAMA. 2004,291 (22):2727. DOI:10.1001/jama. 291.22.2727

26. Simms A., Weston C., West R., Hall A., Batin P., Timmis A. et al. Mortality and missed opportunities along the pathway of care for ST-elevat ion myocardial infarction: a national cohort study. European Heart Journal: Acute Cardiovascular Care. 2015,4 (3):241-53. DOI:10.1177/2048872614548602

27. Fox RAA, FitzGerald G., Puymirat E., Huang W., Carruthers K., Simon T. et al. Should patients with acute coronary disease be stratified for management according to their risk? Derivation, external validation and outcomes using the updated GRACE risk score. BMJ Open. 2014,4 (2):e004425. DOI:10.1136/bmjopen-2013-004425

28. Wilson PWF, DAgostino R., Bhatt DL, Eagle K., Pencina MJ, Smith SC et al. An International Model to Predict Recurrent Cardiovascular Disease. The American Journal of Medicine. 2012,125 (7):695-703. e1. DOI:10.1016/j. amjmed. 2012.01.014

29. Singh M., Rihal CS, Gersh BJ, Roger VL, Bell MR, Lennon RJ et al. Mortality Differences Between Men and Women After Percutaneous Coronary Interventions. Journal of the American College of Cardiology. 2008,51 (24):2313-20. DOI:10.1016/j. jacc. 2008.01.066

30. Chung W-J, Chen C-Y, Lee F-Y, Wu C-C, Hsueh S-K, Lin C-J et al. Validation of Scoring Systems RAat Predict Outcomes in Patients With Coronary Artery Disease Undergoing Coronary Artery Bypass Grafting Surgery: Medicine. 2015,94 (23):e927. DOI:10.1097/MD.0000000000000927